Organon & Co. (NYSE:OGN), a prominent player in the healthcare sector, has been garnering attention from analysts due to its diverse product portfolio and strategic market positioning. The company ...

On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company’s dividend payout, from $0.28 to $0.02 and would “redirect those ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS ...

Access our full analysis report here, it’s free. Branded Pharmaceuticals company Organon (NYSE:OGN) jumped 5.8%. Is now the time to buy Organon? Access our full analysis report here, it’s free.

On Thursday, BNP Paribas (OTC: BNPQY) Exane adjusted its outlook on Organon & Co. (NYSE: OGN), reducing the price target to $16 from the previous $29, while retaining an Outperform rating on the ...

SAN DIEGO, May 23, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co., No. 25-cv-05322 (D.N.J.) – seeks ...

Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April ...

Notably, defendants concealed the high priority of Organon's debt reduction strategy following the Company's acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend.

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of ...

PHILADELPHIA, May 30, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company ...

On May 1, 2025, Organon released its first quarter 2025 financial results, announcing that management had reset the Company’s dividend payout, from $0.28 to $0.02 and would “redirect those ...

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organon & Co. (“Organon” or “the Company ...